Your browser doesn't support javascript.
loading
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Ngo, Bryan; Kim, Eugenie; Osorio-Vasquez, Victoria; Doll, Sophia; Bustraan, Sophia; Liang, Roger J; Luengo, Alba; Davidson, Shawn M; Ali, Ahmed; Ferraro, Gino B; Fischer, Grant M; Eskandari, Roozbeh; Kang, Diane S; Ni, Jing; Plasger, Ariana; Rajasekhar, Vinagolu K; Kastenhuber, Edward R; Bacha, Sarah; Sriram, Roshan K; Stein, Benjamin D; Bakhoum, Samuel F; Snuderl, Matija; Cotzia, Paolo; Healey, John H; Mainolfi, Nello; Suri, Vipin; Friedman, Adam; Manfredi, Mark; Sabatini, David M; Jones, Drew R; Yu, Min; Zhao, Jean J; Jain, Rakesh K; Keshari, Kayvan R; Davies, Michael A; Vander Heiden, Matthew G; Hernando, Eva; Mann, Matthias; Cantley, Lewis C; Pacold, Michael E.
Afiliação
  • Ngo B; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Kim E; Department of Radiation Oncology, Perlmutter Cancer Center and NYU Langone Health, New York, New York.
  • Osorio-Vasquez V; Department of Radiation Oncology, Perlmutter Cancer Center and NYU Langone Health, New York, New York.
  • Doll S; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Bustraan S; Department of Radiation Oncology, Perlmutter Cancer Center and NYU Langone Health, New York, New York.
  • Liang RJ; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Luengo A; Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts.
  • Davidson SM; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Ali A; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey.
  • Ferraro GB; Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts.
  • Fischer GM; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Eskandari R; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Kang DS; Harvard Medical School, Boston, Massachusetts.
  • Ni J; Departments of Translational Molecular Pathology, Melanoma Medical Oncology, Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Plasger A; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Rajasekhar VK; Department of Stem Cell Biology and Regenerative Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California.
  • Kastenhuber ER; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bacha S; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Sriram RK; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Stein BD; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bakhoum SF; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Snuderl M; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Cotzia P; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Healey JH; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Mainolfi N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Suri V; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Friedman A; Department of Pathology, New York University Langone Health, New York, New York.
  • Manfredi M; Department of Pathology, New York University Langone Health, New York, New York.
  • Sabatini DM; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jones DR; Raze Therapeutics, Cambridge, Massachusetts.
  • Yu M; Raze Therapeutics, Cambridge, Massachusetts.
  • Zhao JJ; Raze Therapeutics, Cambridge, Massachusetts.
  • Jain RK; Raze Therapeutics, Cambridge, Massachusetts.
  • Keshari KR; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.
  • Davies MA; Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Vander Heiden MG; Broad Institute, Cambridge, Massachusetts.
  • Hernando E; Department of Radiation Oncology, Perlmutter Cancer Center and NYU Langone Health, New York, New York.
  • Mann M; Metabolomics Core Resource Laboratory, NYU Langone Health, New York, New York.
  • Cantley LC; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Pacold ME; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer Discov ; 10(9): 1352-1373, 2020 09.
Article em En | MEDLINE | ID: mdl-32571778
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Neoplasias Encefálicas / Fosfoglicerato Desidrogenase / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Neoplasias Encefálicas / Fosfoglicerato Desidrogenase / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2020 Tipo de documento: Article